Skip to main content
Log in

Myelodysplastic syndrome

Blast-phase chronic myelomonocytic leukemia: more than just semantics

  • Correspondence
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Margolskee E. Leukemia. 2018 Jun 28. https://doi.org/10.1038/s41375-018-0186-x. [Epub ahead of print] PMID: 29955129.

  2. Patnaik MM, Pierola AA, Vallapureddy R, Yalniz FF, Kadia TM, Jabbour EJ, Lasho T, Hanson CA, Ketterling RP, Kantarjian HM, Tefferi A, Garcia-Manero G. Leukemia. 2018 Apr 25. https://doi.org/10.1038/s41375-018-0143-8. [Epub ahead of print] No abstract available. PMID: 29749401.

  3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.

    Article  PubMed  CAS  Google Scholar 

  4. Patnaik MM, Itzykson R, Lasho TL, Kosmider O, Finke CM, Hanson CA, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014;28:2206–12.

    Article  PubMed  CAS  Google Scholar 

  5. Patnaik MM, Lasho TL, Vijayvargiya P, Finke CM, Hanson CA, Ketterling RP, et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016;6:e385.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  6. Patnaik MM, Wassie EA, Lasho TL, Hanson CA, Ketterling R, Tefferi A. Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome. Am J Hematol. 2015;90:411–6.

    Article  PubMed  Google Scholar 

  7. Patnaik MM, Vallapureddy R, Yalniz FF, Hanson CA, Ketterling RP, Lasho TL, Finke C, Al-Kali A, Gangat N, Tefferi A. Am J Hematol. 2018 Jan;93:65–73. https://doi.org/10.1002/ajh.24939. Epub 2017 Nov 3. PMID: 29023992.

  8. Merlevede J, Droin N, Qin T, Meldi K, Yoshida K, Morabito M, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016;7:10767.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

Download references

Acknowledgements

Current publication is supported in part by grants from the “The Gerstner Family Career Development Award” and the Mayo Clinic Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA. This publication was supported by CTSA Grant Number KL2 TR000136 from the National Center for Advancing Translational Science (NCATS).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mrinal M. Patnaik.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Patnaik, M.M., Tefferi, A. & Garcia-Manero, G. Blast-phase chronic myelomonocytic leukemia: more than just semantics. Leukemia 32, 2093–2094 (2018). https://doi.org/10.1038/s41375-018-0228-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0228-4

  • Springer Nature Limited

Navigation